Delos Wealth Advisors LLC Acquires 100 Shares of Amgen Inc. (NASDAQ:AMGN)

Delos Wealth Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2,500.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 104 shares of the medical research company’s stock after purchasing an additional 100 shares during the quarter. Delos Wealth Advisors LLC’s holdings in Amgen were worth $30,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Fuller & Thaler Asset Management Inc. boosted its holdings in Amgen by 1.7% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after acquiring an additional 193 shares during the last quarter. Diversified Trust Co boosted its holdings in Amgen by 76.8% during the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after acquiring an additional 16,376 shares during the last quarter. Provence Wealth Management Group boosted its holdings in Amgen by 11.9% during the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after acquiring an additional 154 shares during the last quarter. Nicolet Advisory Services LLC boosted its holdings in Amgen by 4.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after acquiring an additional 117 shares during the last quarter. Finally, Platform Technology Partners boosted its holdings in Amgen by 7.4% during the 3rd quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after acquiring an additional 402 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada cut their price target on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. TD Cowen cut their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Truist Financial reissued a “buy” rating and issued a $320.00 price target on shares of Amgen in a report on Friday, April 12th. SVB Leerink downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Finally, BMO Capital Markets boosted their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $305.65.

Amgen Trading Up 1.8 %

AMGN stock traded up $5.55 on Thursday, reaching $312.86. The company’s stock had a trading volume of 2,920,928 shares, compared to its average volume of 2,909,855. The business has a fifty day simple moving average of $276.24 and a two-hundred day simple moving average of $281.92. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The firm has a market cap of $167.83 billion, a PE ratio of 44.69, a PEG ratio of 3.00 and a beta of 0.60. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm’s revenue was up 22.0% on a year-over-year basis. During the same quarter last year, the firm posted $3.98 earnings per share. As a group, research analysts forecast that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.88%. Amgen’s payout ratio is presently 128.57%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.